Adenosine A1 receptor activator T62 NEW
| Price | $89 | $193 | $287 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Adenosine A1 receptor activator T62 | CAS No.: 40312-34-3 |
| Purity: 95.00% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Adenosine A1 receptor activator T62 |
| Description | Adenosine A1 receptor activator T62 is an allosteric enhancer of the adenosine A1 receptor, producing antinociception in animal models of acute pain and reducing hypersensitivity in models of inflammatory and nerve-injury pain[1][2][3]. |
| Animal Research | Intrathecal T62 of Male SpragueDawley rats (250 g) after paw incision surgery with the dose of 0.3 μg, 0.5 μg, 1 μg, and 3 μg, produced a dose-dependent antihypersensitivity effect, with no effect on ambulation or activity level. The ED40 (95% confidence interval) for T62 was 0.77 (0.63-0.91) microg. |
| In vivo | Intrathecal administration of the adenosine A1 receptor activator T62 (0.3-3 μg) in male Sprague-Dawley rats produces a dose-dependent antihypersensitivity effect without affecting ambulation or activity levels[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 75 mg/ml (257.03 mM) |
| Keywords | α2-adrenoceptors | P1 receptor | neuropathic | intrathecal | Inhibitor | inhibit | hypersensitivity | Enhancer | antihypersensitivity | allosteric | Adenosine Receptor | Adenosine A-1 receptor activator T62 | Adenosine A1 receptor activator T62 | adenosine |
| Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Adenosine 5'-monophosphate monohydrate | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline | FK-453 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3360.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1990.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1g |
VIP4Y
|
XIAMEN SINOPEG BIOTECH CO., LTD.
|
2024-07-30 | |
| $89.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY